Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

KD 018

Drug Profile

KD 018

Alternative Names: KD018; PHY-906; YIV906

Latest Information Update: 27 May 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator PhytoCeutica
  • Developer Kadmon Corporation; PhytoCeutica
  • Class Chemoprotectants
  • Mechanism of Action Acetylcholinesterase modulators; Cytochrome P 450 enzyme system inhibitors; Metalloprotease inhibitors; NF-kappa B inhibitors; Opioid delta receptor antagonists; P-glycoprotein inhibitors; Tachykinin receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Colorectal cancer; Gastrointestinal disorders; Liver cancer; Pancreatic cancer

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 28 Jul 2017 Kadmon suspends patient enrolment in a phase II trial for data analysis for Colorectal cancer (Adjunctive treatment, Combination therapy, Metastatic disease, Second-line therapy or greater) in USA (PO) (NCT00730158)
  • 11 May 2015 Discontinued - Phase-I/II for Gastrointestinal disorders (Chemotherapy-induced) in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top